@article {Ferreira Dalla Pria:2023:2637-8329:142,
title = "Tumor Response Metrics in Neuro-Oncology: A Review",
journal = "Neurographics",
parent_itemid = "infobike://asnr/ng",
publishercode ="asnr",
year = "2023",
volume = "13",
number = "3",
publication date ="2023-07-01T00:00:00",
pages = "142-165",
itemtype = "ARTICLE",
issn = "2637-8329",
eissn = "2637-8329",
url = "https://asnr.publisher.ingentaconnect.com/content/asnr/ng/2023/00000013/00000003/art00002",
doi = "doi:10.3174/ng.2100083",
keyword = "WHO = World Health Organization, CP = cross product, CST = computed tomography, RECIST = Response Evaluation Criteria in Solid Tumors, SWI = susceptibility-weighted imaging, T2WI = T2-weighted images, PWI = perfusion-weighted imaging, NANO = Neurologic Assessment in Neuro-Oncology, PR = partial response, ABTI = advanced brain tumor imaging, T1WI = T1-weighted images, SPD = sum of the product of diameters, RANO-LM = Response Assessment in Neuro-Oncology‐Leptomeningeal Metastases, MD = maximum diameter, MRS = magnetic resonance spectroscopy, FLAIR = fluid-attenuated inversion recovery, PD = progressive disease, RANO-BM = Response Assessment in Neuro-Oncology‐Brain Metastases, SLD = sum of longest diameters, CR = complete response, RANO-LGG = Response Assessment in Neuro-Oncology‐Low-Grade Glioma, DWI = diffusion-weighted imaging, RANO = Response Assessment in Neuro-Oncology, iRANO = Immunotherapy Response Assessment in Neuro-Oncology, MR = magnetic resonance, RANO-HGG = Response Assessment in Neuro-Oncology‐High-Grade Glioma",
author = "Ferreira Dalla Pria, H.R. and Pokhylevych, H. and Hassan, A. and Tahon, N.H. and Saleh, M. and Shah, K. and Carter, B.W. and Bhosale, P.R.",
abstract = "Despite the efforts spent in clinical trials in neuro-oncology during the last few decades, many challenges remain in the radiologic evaluation of brain tumors and metastases. This article aims to explain the current use of tumor metrics, especially in phase II clinical trials, to evaluate
response to systemic therapy in neuro-oncology. We will discuss the imaging findings associated with progression and with partial, minor, or complete response to treatment, as well as the method of measurement, the distinction between disease-related and treatment-related changes, and inclusion
of clinical symptoms to define treatment response and progression. The evaluation of response in brain tumors requires metrics that account for differences in response between high- and low-grade gliomas and specific tumor behaviors associated with radiation and immunotherapy, among other
pitfalls. Advanced brain imaging techniques, such as perfusion and permeability imaging, should be incorporated into clinical trials to measure response to novel therapeutic agents more accurately.Learning Objectives: To understand the role of tumor metrics analysis and the main challenges
and pitfalls of applying neuro-oncology imaging criteria",
}